Dalfampridine (4-Aminopyridine)
- Atc Codes:N07XX07
- CAS Codes:504-24-5
- PHARMGKB ID:504-24-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Ampyra.
Drug combinations
Chemistry
Dalfampridine: C~5~H~6~N~2~. Mw: 94.1. (1) 4-aminopyridine; (2) Avitrol; (3) γ-Aminopyridine. CAS 504-24-5.
Pharmacologic Category
Other Miscellaneous Therapeutic Agents; Potassium Channel Blocker. (ATC-Code: N07XX07).
Mechanism of action
Has not been fully elucidated. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.
Therapeutic use
Indicated to improve walking in multiple sclerosis.
Pregnancy and lactiation implications
Based on animal data, may cause fetal harm. Discontinue drug or nursing taking into consideration importance of drug to mother.
Unlabeled use
Contraindications
History of seizure. Moderate or severe renal impairment.
Warnings and precautions
May cause dose-dependent seizures; contraindicated in prior history of seizure; use should be discontinued if seizure occurs. Contraindicated in moderate or severe renal impairment (CrCl ≤50 mL/min); the risk of seizures in mild renal impairment (CrCl: 51-80 mL/min) is unknown. Should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same. Urinary tract infections were reported more frequently in patients receiving this treatment compared to placebo.